Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

TRENDING
Air Taxi Maker EHang Slashes U.S Listing Target to $46 Million
Tencent-Backed iDreamSky in Talks to Buy Rival Gaming Firm Leyou
Sweetome Acquires 2 Units as Homestay Sector Defies Sharing-Economy Gloom
LATEST
Air Taxi Maker EHang Slashes U.S Listing Target to $46 Million
Sweetome Acquires 2 Units as Homestay Sector Defies Sharing-Economy Gloom
Tencent-Backed iDreamSky in Talks to Buy Rival Gaming Firm Leyou
China’s AutoX Applies for License to Test Fully Self-Driving Cars in California
Beijing City Moots Limiting Gym Memberships to Three Months in Prepaid Services Crackdown
Kuaishou Reports Strong Esports User Data Thanks to League of Legends
China’s Top Global Education Ranking Sparks Pride and Controversy
China’s Software Sector Profits Up Nearly 12% in First 10 Months
Chinese-Backed DNA Testing Company Suspends U.S. Business, Lays Off Staff
New Installations of Solar Power Plunge as Subsidies Fade
Nio’s Growth Stagnates as Foreign Adversaries Expand in China
SAIC Taps India Electric Car Market With MG Model
Xiaomi Targets Indian Borrowers with New Online Lending Service
ZTE Partners With Chinese Plane-Maker for In-Flight 5G Internet Project
Chinese Chip Design Firm Goodix Given Nod to Acquire NXP’s Voice and Audio Solutions Business
Former Graft Buster Falls Under Graft Probe
Huawei Sues U.S. Telecoms Regulator Over Sales Ban
Chinese Video Streaming Service iQiyi Eyes Subscribers Abroad and Mulls Price Hikes at Home
ByteDance-Backed App TikTok is Creating Stars and Destroying Lives in India
Nintendo Partners With Tencent to Launch Switch in China
China Approves New Rheumatoid Arthritis Drug

By Zhao Runhua and Di Ning / Jul 24, 2019 04:53 AM / Business & Tech

Photo: Bloomberg

Photo: Bloomberg

Another global pharmaceutical company won government approval to sell a drug to sufferers of rheumatoid arthritis (RA) in China after multiple international companies announced approvals to offer treatments to millions of patients.

Belgium-based UCB was cleared to provide treatment for moderate-to-severe RA patients with Cimzia, a drug the company submitted in 2018 to China’s National Medical Product Administration for review, according to an official release. UCB said Cimzia is its first biologic therapy approved for the China market. The treatment is widely used for cancer and other conditions to restore patients’ immune systems. 

RA is a chronic illness in which a patient’s immune system causes pain by attacking joints. The cause remains unknown. According to a report published by the Chinese Medical Association’s RA group, the Chinese mainland now has around 5 million RA patients.

The effective date and pricing for Cimzia’s sales in China were not available.

An RA drug co-developed by Lilly and Incyte won approval from the Chinese government earlier this month. A Lilly spokesperson told Caixin the price would be decided with careful consideration of Chinese patients’ purchasing capability. Lilly also said it hoped China’s national medical insurance program could support patients’ use of the drug.

Contact reporter Zhao Runhua (runhuazhao@caixin.com)

Share this article
Open WeChat and scan the QR code